A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Intellia Therapeutics, Inc. (“we,” “us,” “our,” “Intellia,” or the “Company”) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, we aim to reset the standard for medicine by durably treating the root causes of disease. For over a decade, Intellia has applied its proprietary technologies and expertise, including CRISPR-based gene editing technologies, oligonucleotides, and lipid nanoparticles (“LNPs”), to develop novel, first-in-class product candidates.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -413M | -413M | -519M | -481M | -474M | -268M |
| EPS | $-3.81 | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 |
| Free Cash Flow | -396M | -396M | -355M | -408M | -347M | -238M |
| ROIC | -67.5% | -53.5% | -59.5% | -45.8% | -38.4% | -25.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.25 | 0.37 | 0.11 | 0.11 | 0.24 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -441M | -441M | -534M | -515M | -458M | -268M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -61.5% | -53.5% | -59.5% | -45.8% | -38.4% | -25.8% |
| Shares Outstanding | 108M | 108M | 99M | 89M | 77M | 71M |
Intellia Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +1.7%.
Intellia Therapeutics, Inc. (NTLA) has a 5-year average return on invested capital (ROIC) of -44.6%. This is below average and may indicate limited pricing power.
Intellia Therapeutics, Inc. (NTLA) has a market capitalization of $1.6B. It is classified as a small-cap stock.
Intellia Therapeutics, Inc. (NTLA) does not currently pay a regular dividend.
Intellia Therapeutics, Inc. (NTLA) operates in the In Vitro & In Vivo Diagnostic Substances industry, within the Healthcare sector.
Intellia Therapeutics, Inc. (NTLA) generated $-396 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Intellia Therapeutics, Inc. (NTLA) has a debt-to-equity ratio of 0.25. This indicates a conservatively financed balance sheet.
Intellia Therapeutics, Inc. (NTLA) reported earnings per share (EPS) of $-3.81 in its most recent fiscal year.
Intellia Therapeutics, Inc. (NTLA) has a return on equity (ROE) of -53.5%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 11 years of financial data for Intellia Therapeutics, Inc. (NTLA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Intellia Therapeutics, Inc. (NTLA) has a book value per share of $6.20, based on its most recent annual SEC filing.